Policy Comments
The priority legislative and regulatory issues that the Cancer Policy Institute focuses on are driven by policy pillars that are centered around the values, needs, and preferences of individuals impacted by cancer. We work in conjunction with patients, patient advocacy organizations, medical associations, and other stakeholders to advance policies aimed at improving access to, affordability of, and quality of care across the cancer continuum.
Letter urging Congress to enact reforms to strengthen the Accelerated Approval drug review pathway.
Letter in support of Washington's request to waive section 1332 in order to moderately expand the number of people with coverage in the state as well as improve the affordability of that coverage.
Letter urging Congress to ensure inclusion of a fix for the Medicaid coverage gap in the Inflation Reduction Act of 2022.
Letter urging Congress to ensure inclusion of critical healthcare provisions for vulnerable communities in its reconciliation package through a solution for the Medicaid coverage gap.
Request to the House Committee on Ways and Means to hold a hearing on H.R. 1946, the Medicare Multi-Cancer Early Detection Screening Coverage Act.
Support of the passage of H.R. 3517, Increasing Access to Osteoporosis Testing for Medicare Beneficiaries Act of 2021 which would improve access to osteoporosis screening by setting a floor rate for reimbursement for osteoporosis screening.
Patient organizations issued this statement on the Kelly v Becerra stating "this litigation directly threatens these benefits and would result in a return to financial and other barriers proven to discourage Americans from obtaining lifesaving, preventive care".